BioXcel Therapeutics, Inc. — Form 8-K

BioXcel Therapeutics (market cap ~$11M) executed its tenth amendment to its credit facility with Oaktree Capital and Q Boost Holding LLC (Qatar Investment Authority) on July 3, 2026. Key changes: deferred $9,016,914 payment due June 30 to July 31; reduced minimum liquidity requirement from $12.5M to $7.5M post-amendment; capitalized accrued interest and added 100 bps amendment fee (1% of outstanding principal) to loan balance; required board-approved Strategic Process Committee (independent director David Mack) with exclusive authority over sale, restructuring, bankruptcy, or equity raise; imposed strict operational controls including bi-weekly 13-week cash flow reporting, 15% variance cap on disbursements, ban on dividends/asset sales/IP transfers/compensation increases through July 31, weekly lender meetings, and requirement to enter definitive agreements for acceptable transaction by July 31 or face default; removed all transfer restrictions on lenders' loan interests.